Summary Nuclear magnetic resonance (NMR) non-invasively measures the apparent diffusion coefficient (ADC) of water, which is sensitive to the biophysical characteristics of tissue. Because anti-cancer treatment alters tumour pathophysiology, tumour ADC may be altered by treatment. In order to test this hypothesis, ADC was measured in s.c. implanted murine RIF-I tumours before and up to 9 days after treatment with cyclophosphamide. A dose-dependent, reversible increase in tumour ADC was observed after cyclophosphamide treatment, which is consistent with an increase in the fraction of interstitial water due to treatmentinduced cell death. Because tumour water ADC is increased substantially at a time when there is no change in tumour volume for a dose which produces minimal cell kill, its measurement could provide a novel means for early detection of response to anti-cancer therapy. If the changes in ADC observed in the present study are evident for commonly used anti-cancer therapies in different tumour types and specific to a therapeutic response, this approach could be broadly applicable as a response predictor since magnetic resonance imaging can be used to measure ADC in human tumours.
The response of human malignancies to commonly used therapy varies markedly even for patients with tumours of the same tissue of origin, stage and classification. Clinical detection of therapeutic efficacy (generally a 50% decrease in tumour volume assessed radiographically) is seldom possible early in the course of treatment when the information could be used to tailor therapy for individual patients. Thus, the need for early predictors of tumour responsiveness to commonly used therapeutic modalities has long been recognised. The ability to predict therapeutic response in individual patients after an initial (or 'test') dose of a fraction of the maximum tolerated dosage would both allow patients with non-responsive tumours to avoid the side-effects and toxicities of a full course of therapy and aid in the selection of patients for the clinical trials of new anti-tumour therapies.
One approach being evaluated as a response predictor is to assess tumours before and during treatment in an attempt to detect changes in the pathophysiology of tumours responding to the initial therapy. Non-invasive methods, including magnetic resonance spectroscopy (e.g. Koutcher et al., 1990; Presant et al., 1994; Sostman et al., 1994) and positron emission tomography (e.g. Ichiya et Wahl et al., 1993; Berlangieri et al., 1994) , are being evaluated for their ability to provide such information. While the initial results using these approaches are encouraging, their ultimate utility remains to be established. Potential weaknesses of these approaches are their limited sensitivity to therapeutic response and coarse spatial resolution. Ideally, one would like to be able to detect the changes associated with a small therapeutic effect at the highest possible spatial resolution. This would both permit intra-tumour heterogeneity to be assessed and allow the smallest possible 'test' dose to be used to identify patients with non-responsive tumours. Although magnetic resonance imaging (MRI) has the spatial resolution needed to assess macroscopic heterogeneity, treatment-induced changes in relaxation times have been reported only for ex vivo measurements (Braunschweiger et al., 1986; Belfi et al., 1991) Water diffusion measured by pulsed-field gradient nuclear magnetic resonance (NMR; Stejskal and Tanner, 1965) is influenced by the restriction of diffusion due to the limited permeability of cell membranes to water (Cooper et al., 1974) . Hence, the water diffusion coefficient measured by NMR is referred to as the apparent diffusion coefficient (ADC) and it is sensitive to the biophysical characteristics of tissue, including the fraction of water in the extracellular space (Latour et al., 1994b) . Because both radiation (Peterson et al., 1976) and chemotherapy (Braunschweiger, 1988) (Le Bihan et al., 1986; Brunberg et al., 1995 Corbett and Valeriote, 1987) .
NMR measurements NMR spectra were acquired on a Bruker Biospec II spectrometer equipped with a 4.7-T horizontal-bore magnet and actively shielded gradients. During NMR observation, the mouse was anaesthetised (1% v/v halothane) and immobilised on a bed that was heated by circulating temperaturecontrolled water. A thermocouple was inserted rectally to monitor mouse core temperature (36.5 ± 0.5°C). The tumour was isolated from the mouse body using a copper shield with a variable diameter hole to minimise signal contamination from normal tissue. Diffusion-weighted 'H-NMR spectra were acquired using a pulsed-field gradient, stimulated echo (PFGSTE) pulse sequence (Tanner, 1970) . Four singleacquisition echoes were acquired for each b-factor using a repetition time of 10 s to avoid saturation effects. The diffusion-weighted b-factor (b = y2G232 (A -3/3)) was varied by changing the diffusion gradient strength (G) from 10 to 30 mT m ', while the duration of the diffusion gradient (6) and the gradient separation time (A) were held constant at 10 ms and 200 ms respectively. The anisotropy of tumour ADC was tested by repeating the measurements in six untreated tumours using the x, y, or z gradient as the diffusion gradient.
Data analysis For a given b-factor, each of the single acquisition echoes were baseline-corrected, zero-filled, Fourier-transformed, and magnitude spectra were calculated. The water PFGSTE amplitudes were measured as peak heights from the four magnitude spectra and the amplitudes were averaged to avoid phase-related motion artifacts. Model fitting and statistical analyses were performed using CSS:STATISTICA/w (StatSoft, Tulsa, OK, USA). Tumour ADC was estimated by non-linear least squares fitting (Quasi-Newton Algorithm) of the PFGSTE amplitude as a function of the diffusionweighting b-factor to the Stejskal- Tanner and Tanner, 1965) , which relates the echo amplitude for a given b-factor (Ab) to ADC; Ab = AO x exp (-b x ADC).
Statistics
Two dependent variables measured across time were analysed: tumour size and tumour ADC. Both variables were measured five times in mice in the no treatment group (days 0, 1, 2, 3 and 4) and eight times in mice in the CP treatment groups (before treatment and days 1-4 and 7-9 after treatment). For both variables, the following analyses were performed. First, a repeated measures two-factor (time, treatment group) analysis of variance (ANOVA) using GeisserGreenhouse-corrected P-values was performed (Kirk, 1982 (Zar, 1984) was performed to determine at which time points the value differed from the pretreatment (day 0) value. A repeated measures two-factor (time, treatment group) ANOVA using Geisser-Greenhousecorrected P-values was also performed for the data from the two CP treatment groups. When a statistically significant interaction was detected between the CP dose and time, a Tukey test was performed to determine at which time points the value differed between the CP doses.
Results
The ADC of tap water in a flask at 20 ± 1°C was measured by the PFGSTE pulse sequence to be 2.15 ± 0.02 (10-9 m2s-'), which is consistent with the literature value (Merboldt et al., 1985) . Figure 1 shows representative PFGSTE data from which tumour water ADC was determined for a control (no treatment) RIF-1 tumour and for RIF-1 tumours 4 days after a single dose of either 150 mg kg-' or 300 mg kg-' CP. The tumour water PFGSTE amplitudes as a function of the diffusion-weighting b-factor were fitted to the Stejskal-Tanner formula (Stejskal and Tanner, 1965) to derive tumour ADC: these ranged from 0.33 x 10-9 m2 s-' to 0.96 x 10-9 m2 s' in all measurements. The maximum difference between tumour ADC measured with the diffusion gradient oriented along the x, y or z-axis of the magnetic field was ± 0.01 x 10-9 m2 s' in six tumours. Consequently, tumour ADC is isotropic in RIF-I tumours.
The time and dose dependence of the size of RIF-I tumours treated with CP is presented in Figure 2 . The pattern of changes over time in tumour size differed among the treatment groups (control, 150 mg kg-' CP and 300 mg kg-' CP) over the first four days of observation (two-factor repeated measures ANOVA; P<0.00001 for the interaction between time and dose). In control tumours the size increased significantly over 4 days of observation (repeated measures ANOVA; P= 0.0004). The tumour size increased significantly compared with the day 0 size on days 2-4 (Tukey test; P<0.001 for all days). Although tumour size did not change significantly over time after treatment with 150mgkg-' CP (P>0.1), treatment with 300mgkg-' did significantly change tumour size (P<0.00005). Tumour size decreased significantly compared with the pretreatment value on days 3 and 4 after a single dose of 300 mg kg-' CP, (P <0.0002 for both days) and returned to a size not significantly different from the pretreatment size by day 7. The effect of CP on tumour size did not differ significantly between the two CP treatment groups (P>0.1).
The time and dose dependence of the ADC in RIF-I tumours treated with CP is presented in Figure 3 [no treatment; n = 6, mean tumour size on day 0 (size 0) = 525 ± 80 (s.e.) mm3]; *, 150 mg kg-CP (n = 6, sizeo = 385 ± 45 mm3); *, 300 mg kg-CP (n = 6, sizeo = 451 ± 46 mm3). Sizeo did not differ among groups (univariate ANOVA, P = 0.2).
Symbols represent mean ± s.e. (bars); +, significant difference from the day 0 size. significantly (P < 0.0005 for both). Tumour ADC significantly increased compared with the pretreatment (day 0) value on days 2 -4 after a single dose of 150 mg kg-' CP (P <0.0002 for all days). After a single dose of 300 mg kg-' CP, tumour ADC increased significantly compared with the pretreatment value from day 2 to day 9 post treatment (P <0.005 for all days). The effect of CP on tumour ADC differed significantly between the two CP treatment groups (P < 0.002). Tumour ADC was higher from days 3 -8 (P <0.05 for all days) in mice treated with 300 mg kg' CP than in mice treated with 150 mg kg-' CP.
Discussion
The principal aim of this study was to determine whether non-invasive measurement of tumour ADC via NMR can detect changes in tumour pathophysiology in response to chemotherapy. These initial results show that ADC is reversibly altered by CP in RIF-1 tumours in the absence of or before decreases in tumour volume. The magnitude and duration of the changes in ADC are dose dependent:
300mgkg-' CP provokes a larger, more sustained increase in ADC than does 150mgkg-' CP. The model recently introduced by Latour et al. (1994b) for diffusion of water in biological systems provides a framework to consider how treatment-induced changes in tumour pathophysiology could account for the changes observed in ADC. This model considers the tissue water existing in two compartments, intra-or extracellular. The variables in the model are the diffusion coefficient and fractional water concentration (vol/vol; due to the fractional concentration occupied by macromolecules) of both compartments, the fraction of extracellular water and the radius and membrane permeability of the cells, which are modelled as spheres. For tumours in vivo, there is a third component from water in the blood. However, since blood occupies less than 5% of RIF-l volume (Braunschweiger, 1988) and the water in blood has a greater apparent diffusion coefficient due to the effect of perfusion (at least ten times greater than ADC in brain; Le Bihan et al., 1986) , the vascular contribution should be minimal over the range of diffusion-weighting b-factors used in this study (0.1 -2.6 x I0-9 s mi-2). Thus, ADC measured in RIF-1 tumours should predominantly reflect intracellular and extracellular, extravascular (i.e. interstitial) water. According 
